Gastrin vaccination against gastrointestinal and pancreatic cancer

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 1, 2006, Pages 122-123

  Rehfeld, Jens F ^a   Goetze, Jens P ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXOID; G 17DT; GASTRIMMUNE; GASTRIN; GASTRIN 17; GASTRIN 17 ANTIBODY; GASTRIN 34; GASTROINTESTINAL HORMONE; HORMONE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; GENE EXPRESSION; HUMAN; LETTER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; VACCINATION;

GASTRINS; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; VACCINATION;

EID: 29744460875     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520500325978     Document Type: Letter

References (11)

1. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer. Nature Rev Cancer 2005;5:459-67.
2. Rehfeld JF, van Solinge WW. The tumor biology of gastrin and cholecystokinin. Adv Cancer Res 1994;63:295-346.
3. Rehfeld JF. Gastrin and cancer. In: Kastin A, editor. Handbook of biologically active peptides. San Diego, Calif., USA: Elsevier Science; 2006. In press.
4. Seva C, Dickinson CJ, Yamada T. Growth-promoting effects of glycine-extended progastrin. Science 1994;265:410-2.
5. Bardram L, Rehfeld JF. Production and evaluation of monospecific antibodies for a processing-independent sequence of human progastrin. Scand J Clin Lab Invest 1989;49:173-82.
6. Makishimi R, Larkin P, Michaeli D, Gaginella TS. Active immunization against gastrin-17 with an N-terminal derived immunogen inhibits gastric and duodenal lesions in rats. Gastroenterology 1994;106:A824.
7. Watson SA, Michaeli D, Grimes S, Morris TM, Robinson G, Varro A, et al. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res 1996;56:880-5.
8. Smith AM, Justin T, Michaeli D, Watson SA. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin Cancer Res 2000;6:4719-24.
9. Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, et al. Phase II study of antigastrin-17-antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 2002;20:4225-31.
10. Aphton Corporation. Gastrin 17 vaccine - Aphton: Antigastrin 17 immunogen G17DT. Biodrugs 2003;17:223-5.
11. Goetze JP, Nielsen FC, Burcharth F, Rehfeld JF. Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 2000;88:2487-94.